论文部分内容阅读
目的 探讨卵巢癌中抑癌基因 p16的表达情况及其与卵巢癌分级分期转移预后的关系。方法 用免疫组化 ABC法检测30例正常卵巢 (NO)、32例卵巢良性肿瘤 (BOT)、8例交界性卵巢肿瘤 (BLT)和 10 3例卵巢癌 (OC)组织中的抑癌基因 p16蛋白表达情况 ,分析 p16蛋白表达与卵巢癌分级分期、转移预后的关系。结果 1p16蛋白表达在恶性、交界性、良性肿瘤组及正常卵巢中的表达率分别为 5 8.3%、81.3%和 2 6 .7%。肿瘤组明显高于正常对照组 (P<0 .0 5 )、恶性组明显低于良性组 (P<0 .0 5 )又明显高于正常组 (P<0 .0 1) ,交界性组也明显低于良性组 (P<0 .0 1)。2 p16蛋白表达与卵巢癌的组织学类型、残余灶大小、淋巴结转移及治疗情况无明显关系。 3分化较差、期别较晚及预后不佳的卵巢癌患者的 p16蛋白表达均明显降低。结论 p16基因在卵巢肿瘤的发生发展中起重要的作用 ,并影响卵巢癌的分化程度、病程进展及临床预后
Objective To investigate the expression of tumor suppressor gene p16 in ovarian cancer and its relationship with the prognosis of staging and metastasis of ovarian cancer. Methods Immunohistochemical ABC method was used to detect the expression of tumor suppressor gene p16 in 30 cases of normal ovary (NO), 32 cases of benign ovarian tumor (BOT), 8 cases of borderline ovarian tumor (BLT) and 103 cases of ovarian cancer Protein expression, analysis p16 protein expression and ovarian cancer staging, metastasis prognosis. Results The expression rates of 1p16 protein in malignant, borderline, benign tumor and normal ovary were 53.3%, 81.3% and 26.7%, respectively. The tumor group was significantly higher than the normal control group (P <0.05), the malignant group was significantly lower than the benign group (P <0.05) and significantly higher than the normal group (P <0.01), borderline group Also significantly lower than the benign group (P <0.01). 2 p16 protein expression and ovarian cancer histological types, residual tumor size, lymph node metastasis and treatment of no significant relationship. 3 poorly differentiated, late and poor prognosis of patients with ovarian cancer p16 protein expression were significantly lower. Conclusion The p16 gene plays an important role in the development of ovarian tumors and affects the differentiation, progression and clinical prognosis of ovarian cancer